Wall Street brokerages forecast that INmune Bio Inc (NASDAQ:INMB) will post earnings of ($0.19) per share for the current quarter, Zacks reports. Zero analysts have made estimates for INmune Bio’s earnings. The firm is scheduled to announce its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that INmune Bio will report full-year earnings of ($0.75) per share for the current financial year. For the next year, analysts forecast that the firm will report earnings of ($0.75) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow INmune Bio.
Separately, Maxim Group set a $13.00 price objective on shares of INmune Bio and gave the company a “buy” rating in a report on Monday.
Shares of NASDAQ:INMB traded down $0.23 on Friday, hitting $10.50. The company had a trading volume of 2,479 shares, compared to its average volume of 15,817. INmune Bio has a 1-year low of $7.00 and a 1-year high of $11.50.
About INmune Bio
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
Featured Article: Fundamental Analysis – How It Helps Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.